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Abstract
Pneumococcal infection is common in children with HIV infection, but osteomyelits is unusual. The
best treatment for bone and joint infection due to antibiotic resistant pneumococci is not known,
especially in immunocompromised children.
A 6 month old girl, infected with HIV by mother to child transmission, had recently started
combination antiretroviral therapy (cART). She presented with osteomyelitis of the left radius
confirmed on bone scan. Blood cultures grew Streptococcus pneumoniae 9S resistant to penicillin,
with reduced susceptibility to ceftriaxone.
Osteomyelitis was treated with parenteral teicoplanin, oral rifampicin and azithromycin. After two
weeks of treatment she developed rash and fever. These were thought to be a drug eruption and
resolved when teicoplanin was stopped. She completed a 3 month course of rifampicin and
azithromycin and continued on cART. She has normal function of her left wrist 18 months after
treatment. She remains on her original cART regimen with an undetectable viral load and normal
CD4 count (34%; 1398 × 106/l).
The combination of rifampicin and azithromycin was well tolerated, simple to administer and
effective. This combination deserves further study in bone and joint infection caused by antibiotic
resistant Gram positive bacteria.
Introduction
Streptococcus pneumoniae is the commonest pathogen caus-
ing bacteraemia in children infected with the human
immunodeficiency virus (HIV). However osteomyelitis is
reported infrequently, and osteomyelitis due to penicillin-
resistant S. pneumoniae has not been reported previously
in this patient group [1].
We report successful treatment of penicillin and cepha-
losporin non-susceptible pneumococcal osteomyelitis in
a child with HIV, using rifampicin and azithromycin.
Case presentation
A 6 month old HIV positive black African girl presented
with a two week history of intermittent fever. Her mother
had been found to be HIV positive when 30 weeks preg-
nant. Mother was given combivir and nevirapine and her
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viral load fell from 20,000 copies/ml to 290 copies/ml at
delivery. The infant was given zidovudine for 4 weeks after
delivery. However pro-viral DNA for HIV was positive at
birth in the infant, implying antenatal infection with HIV.
The infant remained well, thrived and had a CD4 count
above 35%. She was therefore not started immediately on
antiretroviral therapy, but was given prophylactic co-tri-
moxazole.
On presenting with fever aged six months there were no
physical signs of note. Blood cultures were taken which
grew Streptococcus pneumoniae with reduced sensitivity to
penicillin, resistant to trimethoprim but sensitive to
cephalosporins and macrolides. She was given intrave-
nous cefotaxime for 3 days then oral erythromycin for 2
weeks.
On review one month later she had been intermittently
febrile since stopping antibiotics. Repeat blood cultures
showed no growth, but she was given 14 days of
parenteral ceftriaxone empirically. Following this she was
commenced on combination antiretroviral therapy
(cART; zidovudine, lamivudine, abacavir and nevirapine),
because of these symptoms and falling CD4 count
(17%{221 × 106/l}).
She re- presented aged 8 months (one month after starting
cART) with a swollen left wrist, fever and raised C-reactive
protein (86 mg/l). A radio-isotope bone scan was compat-
ible with osteomyelitis of the left radius. Blood cultures
grew  Streptococcus pneumoniae 9S resistant to penicillin
(MIC >2 mg/l) and trimethoprim, with reduced sensitivity
to cephalosporins (MIC 1–2 mg/l), but sensitive to vanco-
mycin, rifampicin and macrolides.
Aspiration of bone was not done since blood cultures
were positive. She was given parenteral teicoplanin (10
mg/kg once daily) with oral rifampicin (10 mg/kg twice
daily) and azithromycin (10 mg/kg once daily). After 2
weeks of treatment she developed rash and fever. These
were thought to be a drug eruption and resolved when
teicoplanin was stopped. She completed a 3 month course
of rifampicin and azithromycin and continued on cART.
Subsequent blood cultures were negative.
Eighteen months after treatment her left wrist is normal,
she remains on her original cART regimen with an unde-
tectable viral load and CD4 count of 34% (1398 × 106/l).
Discussion
S pneumoniae causes 3–6% of bone and joint infections in
children with normal immunity [2,3]. Penicillin and/or
ampicillin are the drugs most commonly used to treat
bone and joint infections due to susceptible strains, whilst
vancomycin and clindamycin or ceftriaxone are used for
penicllin-nonsusceptible strains [3]. The best treatment
for antibiotic resistant pneumococcal bone and joint
infection is not known. Clinical response to treatment was
similar in children with bone and joint infection due to
penicillin non-susceptible pneumococci when compared
with children infected by penicillin susceptible strains [2].
The combination of rifampicin and azithromycin was
effective in treating osteomyelitis caused by a penicillin
and cephalosporin non-susceptible pneumococcus in a
child with HIV. Rifampicin and azithromycin have differ-
ent sites of action in bacteria. This combination has been
shown to be effective in animal models of staphylococcal
osteomyelitis [4]. There is also one case report of an adult
with antibiotic resistant pneumococcal infection in a
prosthetic joint where these antibiotics were successfully
used sequentially, but not in combination [5].
Both azithromycin and rifampicin achieve high levels in
bone. However azithromycin monotherapy is ineffective
for the treatment of experimental staphylococcal osteo-
myelitis, [6] whilst rifampicin monotherapy is associated
with the emergence of rifampicin resistance.
In the UK macrolide resistance is more common in peni-
cillin non-susceptible S pneumoniae, making macrolides in
general less useful for treating osteomyelitis. However in
this case the isolate was macrolide sensitive, despite peni-
cillin and cephalosporin resistance.
Rifampicin can also interact with anti-retroviral drugs,
especially protease inhibitors and nevirapine. Current
advice is that low dose ritonavir/protease inhibitors com-
binations or nevirapine should not be given with
rifampicin [7]. In our case we chose to continue nevirap-
ine since we were unable to use efavirenz, due to the
child's young age (less than 3 years), and felt there was no
advantage in changing to a protease inhibitor. The child's
viral load became undetectable on cART, despite the use
of rifampicin.
Other antibiotics may have been effective in this case, but
also had potential drawbacks. Ceftriaxone may be effec-
tive for non-ceftriaxone susceptible pneumococcal infec-
tion outside the central nervous system, as long as the
MIC is < 2.0 mg/l [8]. However this reported series did not
include any children with osteomyelitis. We felt we could
not rely on this agent in an immunocompromised child
with osteomyelitis, particularly since she had recently
received a two week course of ceftriaxone and failed to
respond clinically. Vancomycin is suggested for cepha-
losporin insensitive pneumococcal meningitis [9], but
may have decreased effectiveness in bone and is unsuita-
ble for outpatient therapy. We were unable to continue
teicoplanin because of a drug eruption. The two weeks ofPublish with BioMed Central    and   every 
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teicoplanin our patient received was unlikely to have been
sufficient treatment. Clindamycin is active in animal
models of staphylococcal osteomyelitis [6]. However the
suspension has a very poor taste, making it inappropriate
in young children for the prolonged oral administration
needed to treat osteomyelitis. Linezolid is active against
pneumococci, and may have been effective [9]. However
long term use can produce bone marrow depression. This
would have been our choice if the child had failed to
respond to azithromycin and rifampicin.
Preventive strategies against pneumococcal disease may
have been useful in this child. Prophylactic co-trimoxa-
zole gives some protection against bacterial infection in
HIV positive children, but the organism in this case was
trimethoprim resistant. Conjugate pneumococcal vaccine
provides some protection, even in HIV positive children
[10]. A 7 valent conjugate pneumococcal vaccine is now
recommended for all HIV positive children in the UK.
This may have given some protection against the pneumo-
coccal serotype in this case by cross protection from the 9F
component of the vaccine.
Conclusion
The combination of rifampicin and azithromycin was
well tolerated, simple to administer and effective in treat-
ing penicillin and cephalosporin insensitive pneumococ-
cal osteomyelitis. This combination deserves further study
for treatment of bone and joint infections, especially
those due to antibiotic resistant Gram positive bacteria.
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